Aurinia Pharmaceuticals earnings date
Aurinia Pharmaceuticals (IKAP) Q4 2025 Earnings Report
DE:IKAP Q4 2025 EPS Results
- Actual EPS
- EUR 1.36
- Consensus EPS
- EUR 0.19
- Beat/Miss
- Beat by +EUR 1.17
- One Year Ago EPS
- EUR 0.01
DE:IKAP Q4 2025 Revenue Results
- Actual Revenue
- EUR 68.60M
- Expected Revenue
- EUR 66.45M
- Beat/Miss
- Beat by +EUR 2.15M
- YoY Revenue Growth
- +28.81%
Earnings Announcement Details
- Quarter
- Q4 2025
- Date
- 02/26/2026
- Time
- Before Open
- Conference Call
- Thursday, February 26, 2026
Aurinia Pharmaceuticals's next earnings date is estimated for March 4, 2027, based on past reporting schedules.
Q4 2025 Earnings Call Audio
Q4 2025 Earnings Slide Deck
No slide deck is available for this earnings event.
Q4 2025 Earnings Call Summary
The call highlights robust commercial momentum for LUPKYNIS with double-digit top-line growth, materially improved cash generation, a strong balance sheet and share repurchases. Management provided constructive 2026 guidance and disclosed promising early clinical results for aritinercept. Offsetting these positives are a significant one-time tax benefit that materially boosted reported net income, termination of a pediatric study (creating regulatory follow-up risk), emerging competition (Gazyva), limited near-term transparency on quarterly performance, and early-stage development uncertainties (ADAs). Overall, the positives—sustained product revenue growth, strong cash flow, and advancing pipeline—outweigh the headwinds, though some risks remain.
On the call Aurinia provided 2026 guidance of total revenue of $315–$325 million (up 11%–15% vs. 2025) and net product sales of LUPKYNIS of $305–$315 million (up 12%–16% vs. 2025); that outlook is framed by FY‑2025 results of total revenue $283.1M (up 20% vs. $235.1M in 2024, or +26% excluding a $10M 2024 milestone), LUPKYNIS sales $271.3M (up 25% YoY), net income $287.2M (driven in part by a $173M income tax benefit), diluted EPS $2.07, operating cash flow $135.7M (up 206% YoY), cash and investments of $398M, and recent share repurchases of 12.2M shares for $98.2M that reduced fully diluted shares from 149.8M to 139.7M; Q4 highlights included revenue $77.1M, LUPKYNIS sales $74.2M (both +29% YoY), Q4 net income $210.8M (driven by a $175.1M tax benefit), diluted EPS $1.53, and Q4 operating cash flow $45.7M (up 52% YoY).
- Strong LUPKYNIS Commercial GrowthNet product sales of LUPKYNIS for full year 2025 were $271.3M, up 25% year-over-year from $216.2M. Management reported LUPKYNIS sales grew 25% in 2025 and expects 2026 net product sales of $305M–$315M (up 12%–16% vs. 2025).
- Quarterly Revenue and Sales UpsideTotal revenue for Q4 2025 was $77.1M, up 29% from $59.9M in Q4 2024. Q4 net product sales of LUPKYNIS were $74.2M, up 29% from $57.6M in Q4 2024.
- Substantial Improvement in Profitability and EPSReported net income for FY2025 was $287.2M (vs. $5.8M in 2024, up 4,852%) and diluted EPS was $2.07 (up 5,075% from $0.04). Q4 2025 diluted EPS was $1.53 (up 15,200% from $0.01).
- Strong Cash Generation and Balance Sheet ActionsCash flows from operating activities for FY2025 were $135.7M, up 206% from $44.4M in 2024; Q4 cash flow from ops was $45.7M, up 52% YoY. Cash, cash equivalents and investments totaled $398M (vs. $358.5M at 12/31/2024). Company repurchased 12.2M common shares for $98.2M, reducing fully diluted shares from 149.8M to 139.7M.
- 2026 Revenue Guidance Reflects Continued GrowthCompany expects total revenue of $315M–$325M for 2026 (up 11%–15% vs. 2025) and net product sales of $305M–$315M (up 12%–16% vs. 2025), reflecting continued commercial momentum.
- Promising Early-Stage Clinical Progress for AritinerceptAritinercept (dual BAFF–APRIL inhibitor) completed Phase I single-ascending-dose testing with good tolerability. Single doses produced robust, durable reductions in immunoglobulins supportive of once-monthly dosing. Company initiated a clinical study in one autoimmune indication and plans a second study in H1 2026; additional details expected in Q2 2026.
DE:IKAP Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 04, 2027 | 2026 (Q4) | 0.19- | 1.36 | ― | ― |
| Oct 30, 2026 | 2026 (Q3) | 0.200.20 | 0.2 | 0.00% (+0.00) | |
| Aug 06, 2026 | 2026 (Q2) | 0.210.25 | 0.14 | 75.00% (+0.11) | |
| May 07, 2026 | 2026 (Q1) | 0.170.22 | 0.14 | 56.25% (+0.08) | |
| Feb 26, 2026 | 2025 (Q4) | 0.191.36 | 0.01 | 15200.00% (+1.35) | |
| Nov 04, 2025 | 2025 (Q3) | 0.140.20 | 0.09 | 130.00% (+0.12) | |
| Jul 31, 2025 | 2025 (Q2) | 0.130.14 | 0.01 | 1500.00% (+0.13) | |
| May 12, 2025 | 2025 (Q1) | 0.090.14 | -0.06 | 328.57% (+0.20) | |
| Feb 27, 2025 | 2024 (Q4) | -0.010.01 | -0.17 | 105.26% (+0.18) | |
| Nov 07, 2024 | 2024 (Q3) | 0.010.09 | -0.08 | 211.11% (+0.17) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

